Withdrawal, treatment & continuity of care

Concentrated 7-OH can produce a dependence pattern more like a short-acting opioid than traditional, low-concentration kratom use. In heavily dependent patients, the day may narrow around avoiding withdrawal: dosing on waking, dosing overnight, carrying product everywhere, redosing every one to three hours, escalating the labelled amount per unit, and eventually using chiefly to feel normal rather than intoxicated.^E25E29

Patients describe craving and compulsive redosing alongside anxiety, inner restlessness, irritability, dysphoria, yawning, sweating, chills, myalgias, tremor, restless legs, abdominal cramping, nausea, diarrhoea, tachycardia, insomnia, fatigue, low mood, and impaired concentration. Published cases also describe rapid tolerance, failed efforts to stop, and substantial functional or financial harm.^{E25E26E27E28E29}

The patient may not identify this as opioid use. They may accurately report that they bought a supplement, a shot, a tablet, a gummy, or a film. That history should change the opening question, not lower the clinical concern. Product identity also matters: purified 7-OH, mitragynine-containing mixtures, pseudoindoxyl, other analogues, and mislabeled products cannot be assumed to have the same withdrawal course.

A related-compound report should not be folded into this curve: a 2026 mitragynine pseudoindoxyl case involved nine 20-mg doses per day, nocturnal dosing, COWS 31, hypertension, and tachycardia. It is clinically important, but pseudoindoxyl is not typical direct 7-OH exposure.^E56

The Clinical Opiate Withdrawal Scale (COWS) remains useful for structured assessment of objective opioid-withdrawal signs, but it has not been validated for concentrated 7-OH. A published patient using approximately 360 mg/day had nausea, diarrhoea, cramping, restlessness, chills, clamminess, and anxiety about 48 hours after the last 30-mg dose, yet the recorded COWS was 5.^E25

One case does not prove that COWS systematically underestimates this syndrome. It does show why a modest score must not overrule a coherent history of high-frequency, high-dose use and functional distress. At the same time, a subjective complaint alone must not trigger standard-dose induction before convincing objective withdrawal is present.

Document COWS, but add the labelled and estimated daily exposure, dosing interval, nighttime dosing, time to interdose withdrawal, sleep loss, dysphoria, anxiety, craving, failed stop attempts, objective gastrointestinal and autonomic findings, coexposures, medications, and the patient’s ability to remain safe while waiting. Routine opiate immunoassays may be negative and should not be used as a treatment gatekeeper.^E25

The best current evidence supports treating the opioid component of significant 7-OH dependence seriously and pragmatically with established medications for opioid use disorder. The 7-OH-specific evidence is encouraging but small, retrospective, and without a comparator.^E26E51

In a 2026 nine-patient retrospective series, six patients received low-dose buprenorphine initiation and three standard initiation. Eight of nine initiated and stabilised; the series reported no precipitated withdrawal or adverse events, and most patients reported improvement at follow-up.^E26

That is a useful treatment signal, not a validated protocol, dose-conversion rule, or efficacy estimate. The cohort was small, retrospective, low-barrier telehealth care without a comparator; published case reports are likewise not a universal induction schedule.^E25E26E27

1. Characterise the exposure. Ask specifically about kratom, 7-OH, 7-hydroxy, shots, tablets, films, gummies, and products obtained from smoke shops, gas stations, or online. Record units, label strength, daily amount, redosing interval, nighttime dosing, route, duration, cost, last use, prior stopping attempts, and coexposures.
2. Establish the clinical objective. Clarify whether the immediate goal is supervised cessation, buprenorphine maintenance, transition to methadone, acute stabilisation, treatment of a mixed-substance syndrome, or short-term stabilisation while the exposure is clarified.
3. Determine dependence severity and risk. Identify interdose withdrawal, loss of control, functional impairment, failed self-cessation, OUD features, withdrawal risk from alcohol or benzodiazepines, and medical or psychiatric instability.
4. Match the setting to current risk. Select the least restrictive setting that can safely provide monitoring, medication access, and rapid escalation. A high daily amount alone does not determine level of care; comorbidity, coexposures, safety, housing, and follow-up reliability matter.
5. Prevent substitution and plan safety before supply changes. Address counterfeit pills and fentanyl explicitly, provide naloxone, involve a family member or caregiver where appropriate, arrange rapid follow-up, and give the patient a named escalation contact.

Precipitated withdrawal is an abrupt worsening after buprenorphine displaces a higher-efficacy opioid agonist before sufficient spontaneous withdrawal has developed. It can include sudden escalation of pain, restlessness, vomiting, diarrhoea, sweating, piloerection, tachycardia, panic, and a sharp rise in withdrawal score. Management depends on severity, setting, and differential diagnosis; severe agitation, delirium, respiratory compromise, or diagnostic uncertainty warrants emergency or higher-level care.^E28

Home initiation may fit a selected patient with clear instructions, reliable communication, and a rapid contact pathway. Observed or closely supervised initiation is preferable with high-frequency dosing, uncertain products, prior precipitated withdrawal, significant coexposures or comorbidity, unstable housing, or unreliable follow-up. The source materials intentionally do not provide a fixed 7-OH-specific milligram-by-day ladder: dosing must be clinician-selected and protocol-based, not improvised from an uncertain label.

Methadone is an evidence-based medication for OUD and may be appropriate when buprenorphine is not preferred, is not tolerated, or has repeatedly been unsuccessful. Ongoing treatment generally proceeds through the legally appropriate opioid-treatment-programme pathway. A published 7-OH case used methadone during acute stabilisation before transition to buprenorphine; a mixed kratom/7-OH 14-patient programme series reported high retention without reported adverse events. Neither establishes a dose-conversion rule or universal sequence.^E27E50E51

Extended-release naltrexone may suit a selected patient who prefers an antagonist approach and can complete an adequate opioid-free interval. The interval is the practical problem: naltrexone can precipitate severe withdrawal when physiological dependence remains, and direct purified-7-OH clearance data are too limited to define a reliable universal abstinence interval. A negative routine opioid screen does not establish readiness.^E53

Adjunctive care can make initiation, monitored withdrawal, or a carefully supervised non-MOUD plan more tolerable. Select it from the full medication list, vital signs, organ function, pregnancy status, interaction profile, and misuse risk. Symptom relief does not provide opioid-receptor stabilisation or prevent relapse.

• Do not treat concentrated 7-OH as “just kratom”. Under-triage makes an isolated, high-risk withdrawal more likely.
• Do not let a low COWS end the conversation. Equally, do not initiate standard buprenorphine on subjective distress alone without objective withdrawal.
• Do not use a fixed hour count as the sole trigger for standard induction. Product identity, repeated dosing, metabolic tail, and direct high-dose 7-OH kinetics are too uncertain.
• Do not build treatment around an unverified retail label or a routine negative opioid screen. History, examination, product evidence, and targeted testing when available are more informative.
• Do not offer abrupt cessation plus willpower as the whole plan. If a patient declines MOUD, provide a structured, monitored harm-reduction plan with an easy route back to treatment.
• Do not advise self-treatment with street opioids, counterfeit tablets, borrowed prescriptions, alcohol, or sedatives. Address fentanyl-substitution risk directly, before the patient is desperate.
• Do not discharge without naloxone and a follow-up pathway. Risk persists during ongoing use, transition, relapse, and reduced tolerance after abstinence.

A sudden supply interruption can generate many simultaneous requests for care. Sending every dependent patient to residential detoxification would consume beds needed for acute medical, psychiatric, and social indications, while delaying medication treatment for people who can safely begin outpatient care. The outpatient-compatible nine-patient buprenorphine series is encouraging, but it does not by itself prove a system-wide capacity model.^E26

The practical default is the least intensive setting that is safe, with escalation driven by medical and psychiatric risk, high-risk coexposures, inability to maintain safety or hydration, and inability to obtain reliable follow-up — not by withdrawal severity alone. This is a practice-based public-health argument, not a controlled trial result.

Health systems can prepare by adding 7-OH product names to intake screening; identifying who can initiate buprenorphine; creating standard and low-dose options; defining outpatient exclusion criteria; coordinating pharmacy access, naloxone, rapid follow-up, and higher-acuity referrals; and tracking product, dose, interval, induction, and outcome. See the action plan for system-level preparation.

Induction is not the finish line. For patients meeting OUD criteria or showing severe compulsive use, ongoing buprenorphine or methadone maintenance may be safer than a rapid taper. There is no evidence-based 7-OH-specific maintenance duration; duration should be individualised to remission, stability, patient goals, relapse history, pain, psychiatric illness, and exposure risk.^E51

Early and frequent follow-up should review withdrawal and craving, continuing 7-OH or other substance use, sleep recovery, pain, anxiety, depression, trauma symptoms, medication effects, adherence, diversion risk, naloxone access, and the patient’s goals. Recovery supports can be offered without making medication contingent on counselling attendance.

Prescribe or dispense naloxone whenever possible and counsel household members. Overdose risk persists because product strength is uncertain, sedative co-use may continue, relapse or substitution may involve fentanyl, and tolerance falls after abstinence. If overdose is suspected, give naloxone, call emergency services, support breathing, position the person to reduce aspiration risk, and remain with them.^E52

A return to use is not treatment failure. It is a reason for rapid, non-punitive reassessment of medication, safety, sleep, pain, psychiatric symptoms, supports, and level of care.